STOCK TITAN

FMC Corporation and Corteva Expand Access to Breakthrough Rimisoxafen Herbicide Technology

(Neutral)
(Neutral)
Tags

FMC (NYSE:FMC) and Corteva announced a co-exclusive strategic supply and license agreement for rimisoxafen, covering corn and soybean markets in North and South America through the next decade.

FMC keeps ownership, supplies the active ingredient, receives a $200 million prepurchase payment, and targets first sales by decade-end, pending approvals.

Loading...
Loading translation...

Positive

  • Co-exclusive rimisoxafen supply and license agreement across Americas corn and soybean markets
  • FMC retains full ownership of rimisoxafen and supplies Corteva with active ingredient
  • Corteva to make a $200 million USD initial prepurchase payment to FMC
  • Agreement duration extends through the next decade, supporting long-term collaboration
  • Both companies can develop exclusive premix formulations for key row crops
  • HRAC classification as industry’s first dual mode of action herbicide technology

Negative

  • First commercial rimisoxafen sales only anticipated by end of the decade
  • Commercialization timing depends on receiving applicable regulatory approvals
  • Additional financial and contractual terms of the agreement remain undisclosed

News Market Reaction – CTVA

+0.65%
+0.65% Session close to close

In the Jun 17 session, CTVA gained 0.65%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement outlines a long-term co-exclusive agreement between Corteva and FMC to expand rimi...
Analysis

This announcement outlines a long-term co-exclusive agreement between Corteva and FMC to expand rimisoxafen herbicide technology across the Americas. Corteva will make a $200 million prepurchase payment and develop its own premix products, with first sales anticipated by the end of the decade, subject to approvals. In context of prior strong 1Q 2026 results and an upcoming corporate separation, investors may track adoption rates, regulatory milestones, and how this technology complements Corteva’s crop protection strategy.

Key Figures

Prepurchase payment: $200 million
1 metrics
Prepurchase payment $200 million Initial prepurchase payment Corteva will make to FMC under agreement

Historical Context

5 past events · Latest: Jun 10 (Neutral)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Jun 10 Conference participation Neutral -0.7% Management presenting at Wolfe’s Materials of the Future conference.
May 21 Earnings schedule Neutral +0.3% Announcement of 2Q 2026 earnings release and webcast dates.
May 12 Separation planning Positive +0.9% Designation of future headquarters for the two post-separation companies.
May 07 Conference appearance Neutral +2.6% CEO and CFO speaking at BMO Global Farm to Market conference.
May 05 Quarterly results Positive -2.5% Strong 1Q 2026 results with reaffirmed 2026 outlook and capital plans.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has mostly seen price moves align with underlying tone, but strong fundamental results on May 5 were followed by a negative reaction, indicating occasional sell-the-news behavior.

Recent Company History

Over the last few months, Corteva has mixed operational strength with strategic repositioning. On May 5, 2026, it reported strong 1Q 2026 results and reaffirmed its 2026 outlook, yet shares fell 2.54%. Subsequent conference participation announcements and an earnings-date release saw modest positive or small negative moves. A key structural milestone came on May 12, 2026 with headquarters plans for two future companies ahead of the planned 4Q 2026 separation, which was followed by a 0.92% gain.

Key Terms

herbicide-resistant, amaranthus, dual mode of action, active ingredient
4 terms
herbicide-resistant medical
"control herbicide-resistant weeds, including Amaranthus species – the number one"
Herbicide-resistant describes plants that survive otherwise effective weed-killing chemicals, either because they were bred or engineered to tolerate those chemicals (common in some crops) or because wild weeds have evolved resistance. For investors, it matters because resistance changes farm costs, yields and product demand—driving spending on different chemicals, seeds or farm practices, influencing agricultural company revenues and regulatory or market risks.
amaranthus medical
"including Amaranthus species – the number one weed resistance challenge"
A group of plants that includes edible leafy greens and grain-like seeds, as well as common weeds; some varieties are grown as food crops while others invade farm fields. Think of it like a plant family that can be either a salad ingredient or an unwanted guest in a garden. Investors care because amaranthus affects agricultural production, seed and food markets, crop yields and costs, and can influence companies focused on seeds, farming technology and weed control.
dual mode of action technical
"this groundbreaking dual mode of action herbicide technology."
Dual mode of action describes a medical product that works through two different biological or physical processes to produce its effect — for example one component may directly target disease-causing agents while the other reduces symptoms or protects tissue. Investors care because two complementary ways of working can make a product more effective, broaden its uses and raise barriers to competitors, but they can also increase development complexity, regulatory scrutiny and costs.
active ingredient technical
"FMC retains all rights of ownership to rimisoxafen and will supply Corteva with the active ingredient."
The active ingredient is the specific chemical or biological substance in a medicine, vaccine, or consumer product that produces the desired therapeutic effect—like the engine in a car that does the actual work. Investors care because the active ingredient determines a product’s effectiveness, safety profile, manufacturing complexity, patent protection, and regulatory approval prospects, all of which directly affect sales potential, development costs, and business risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Strategic supply and license agreement will accelerate access for North and South American corn and soybean growers

Strategic supply and license agreement will accelerate access for North and South American corn and soybean growers.

PHILADELPHIA and INDIANAPOLIS, June 16, 2026 /PRNewswire/ -- FMC Corporation (NYSE: FMC) and Corteva, Inc. (NYSE: CTVA), two leading global agricultural science and innovation companies, today announced a co-exclusive strategic supply and license agreement that will expand access to FMC's rimisoxafen technology across North and South America corn and soybean markets, adding an important new tool to each company's respective herbicide portfolio. This collaboration will enable more growers across the Americas to control herbicide-resistant weeds, including Amaranthus species – the number one weed resistance challenge globally in soybeans and critical in cross-crop pressure in corn – with this groundbreaking dual mode of action herbicide technology.

"This agreement ensures that more growers across the Americas will have access to rimisoxafen, one of the most innovative herbicide technologies developed in decades," said Leonardo Bastos, FMC vice president and chief marketing officer. "By working with Corteva, we are expanding the reach of this breakthrough technology to help growers effectively manage resistant weeds that threaten their productivity and profitability. Together, we are bringing growers a solution they urgently need. At the same time, FMC is committed to unlocking the full global potential of rimisoxafen across additional crops and geographies, reflecting our confidence in this molecule as a cornerstone of our innovation pipeline."

Under the terms of the agreement, which extends through the next decade, FMC retains all rights of ownership to rimisoxafen and will supply Corteva with the active ingredient. Both companies will develop and commercialize their own exclusive premix formulations for the corn and soybean markets across North and South America, while FMC will continue to develop additional rimisoxafen-based products for other crops and geographies globally. Corteva will make an initial prepurchase payment of $200 million USD for product to be supplied by FMC. Together, both companies are committed to ensuring broad availability of this innovative technology and rapid adoption, supporting growers with durable weed management solutions for years to come.

"By collaborating with FMC on rimisoxafen, we are expanding our ability to provide growers with advanced weed control tools that complement our portfolio," said Cynthia Ericson, Corteva vice president, weed control segment. "This agreement supports our long-term strategy of forging new collaborations that drive value for farmers, as well as a unique growth opportunity with attractive economics for Corteva above our current deep crop protection pipeline set to launch over the next decade."

Rimisoxafen's dual mode of action creates a significantly higher barrier to resistance development compared to single mode of action herbicides, providing growers with an essential tool for managing weeds like palmer amaranth and waterhemp that have become resistant to multiple herbicide classes and cost farmers billions of dollars annually in lost yield. First commercial sales are anticipated by the end of the decade, pending applicable regulatory approvals. The Herbicide Resistance Action Committee recently classified rimisoxafen as the industry's first dual mode of action herbicide, recognizing its unique ability to control troublesome broadleaf weeds that threaten crop yields and farm profitability.

Additional terms of the agreement were not disclosed.

About FMC

FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC's innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protecting the environment. FMC is committed to discovering new herbicide, insecticide and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. Visit fmc.com to learn more and follow us on LinkedIn®.

About Corteva
Corteva, Inc. (NYSE: CTVA) is a global pure-play agriculture company that combines industry-leading innovation, high-touch customer engagement and operational execution to profitably deliver solutions for the world's most pressing agriculture challenges. Corteva generates advantaged market preference through its unique distribution strategy, together with its balanced and globally diverse mix of seed, crop protection, and digital products and services. With some of the most recognized brands in agriculture and a technology pipeline well positioned to drive growth, the Company is committed to maximizing productivity for farmers, while working with stakeholders throughout the food system as it fulfills its promise to enrich the lives of those who produce and those who consume, ensuring progress for generations to come. More information can be found at www.corteva.com.

Always read and follow all label directions, restrictions and precautions for use. Products listed here may not be registered for sale or use in all states, countries or jurisdictions.

Statement under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995:  FMC, Corteva and their respective representatives may from time to time make written or oral statements that are "forward-looking" and provide other than historical information, including statements contained in this press release, in each company's other filings with the SEC, and in presentations, reports or letters to their stockholders.

In some cases, the companies identified these forward-looking statements by such words or phrases as "outlook", "will likely result," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends" or similar expressions identifying "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words or phrases. Such forward-looking statements are based on the companies' current views and assumptions regarding future events, future business conditions and the outlook for the companies based on currently available information. The forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. These statements are qualified by reference to the risk factors included in Part I, Item 1A of each company's Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K"), the section captioned "Forward-Looking Information" in Part II of the 2025 Form 10-K and to similar risk factors and cautionary statements in all other reports and forms filed with the Securities and Exchange Commission ("SEC"). We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made.  Forward-looking statements are qualified in their entirety by the above cautionary statement.

We specifically decline to undertake any obligation, and specifically disclaim any duty, to publicly update or revise any forward-looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as may be required by law.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/fmc-corporation-and-corteva-expand-access-to-breakthrough-rimisoxafen-herbicide-technology-302802332.html

SOURCE FMC Corporation

FAQ

What did FMC (NYSE:FMC) announce with Corteva about rimisoxafen herbicide on June 16, 2026?

FMC and Corteva announced a co-exclusive strategic supply and license agreement for FMC’s rimisoxafen herbicide technology. According to FMC, the deal expands access across North and South American corn and soybean markets and strengthens both companies’ weed control portfolios over the next decade.

How much is Corteva paying FMC under the new rimisoxafen supply agreement (NYSE:FMC)?

Corteva will make an initial prepurchase payment of $200 million USD to FMC for rimisoxafen product. According to FMC, this payment relates to product FMC will supply, while FMC retains ownership of the active ingredient and continues broader global development.

When are rimisoxafen herbicide commercial sales expected for FMC (NYSE:FMC) and Corteva?

First commercial sales of rimisoxafen are anticipated by the end of the decade. According to FMC, this timing depends on receiving applicable regulatory approvals, after which both companies plan to market their own premix formulations for corn and soybean growers.

What makes FMC’s rimisoxafen herbicide technology important for corn and soybean growers?

Rimisoxafen is described as a groundbreaking dual mode of action herbicide that targets resistant weeds. According to FMC, it helps manage Amaranthus species like palmer amaranth and waterhemp, which cause major yield losses and complicate weed resistance management in soybeans and corn.

How will the FMC and Corteva rimisoxafen agreement impact weed resistance management?

The agreement aims to broaden access to rimisoxafen, supporting more durable weed control strategies. According to FMC, its dual mode of action offers a higher barrier to resistance versus single mode herbicides, helping growers manage troublesome broadleaf weeds across key American row-crop markets.

What rights do FMC (NYSE:FMC) and Corteva hold under the rimisoxafen agreement?

FMC retains all ownership rights to rimisoxafen and will supply Corteva with the active ingredient. According to FMC, both companies may develop and commercialize their own exclusive premix formulations for corn and soybeans in North and South America under this co-exclusive arrangement.